Johnson & Johnson
Executive Summary
Ortho Biotech extends a March 1990 agreement with Xoma which covers the development of Xoma's CD5+ and other immunoconjugates for graft v. host disease and organ transplant rejection to include Type I diabetes and other uses except rheumatoid arthritis. On June 10, an FDA advisory panel recommended approval of CD5+ in treating GvHD. The drug is in Phase I for the treatment of Type I diabetes and Phase II for inflammatory bowel disease. Under a 1990 pact, Ortho will market the product under the Orthozyme brandname.